For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Blog
Trump’s State of the Union: A closer look at the claims
Last night, President Trump delivered a State of the Union address filled with optimism, applause lines, and bold claims about the country’s direction. There…
Search Posts
Op-Eds
EU Over-REACH
The latest mutation of the Precautionary Principle–which would heavily regulate, if not prohibit, any product, technology or activity that is in any way incomplete–is…
Op-Eds
Europe’s REACH Exceeds Its Scientific Grasp
European regulatory officials have raised hostility to technological innovation to an art form. Their current medium of choice is the Precautionary Principle, which holds…
Op-Eds
Stockholm Syndrome
The Stockholm Convention on Persistent Organic Pollutants (POPs) is a United Nations Environment Programme Convention, which bans or regulates industrial chemicals and pesticides. The…
Op-Eds
Brussels’ Bad Science Will Cost the World Dear
Regulatory officials in the European Union seem to be ignorant of the rule of holes: when you are in one, stop digging. Numerous analyses…
Op-Eds
The Brundtland Legacy
The five-year tenure of Gro Harlem Brundtland as head of the World Health Organisation (WHO) has just come to an end. She leaves behind…
Op-Eds
Los Beneficios de la Biotecnologa
Click on pdf link above to obtain full article…